Biricodar

Biricodar
Clinical data
ATC code	none;
Identifiers
	IUPAC name 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;
CAS Number	174254-13-8 ;
PubChem CID	3037617;
ChemSpider	2301309 ;
UNII	9WQP0L619L;
ChEMBL	ChEMBL350775 ;
CompTox Dashboard (EPA)	DTXSID50893944 ;
Chemical and physical data
Formula	C34H41N3O7
Molar mass	603.716 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C(=O)c1cc(OC)c(OC)c(OC)c1)N4[C@H](C(=O)OC(CCCc2cccnc2)CCCc3cccnc3)CCCC4;
	InChI InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1 ; Key:CGVWPQOFHSAKRR-NDEPHWFRSA-N ;
	(verify)

Biricodar or incel (INN, codename VX-710) was a pharmaceutical drug under development by Vertex Pharmaceuticals to help treat ovarian cancer patients.^[1] The drug never reached the market.

References

^ Dey S (May 2002). "Biricodar. Vertex Pharmaceuticals". Current Opinion in Investigational Drugs. 3 (5). London, England: 818–23. PMID 12090559.

Nobili S, Landini I, Giglioni B, Mini E (July 2006). "Pharmacological strategies for overcoming multidrug resistance". Current Drug Targets. 7 (7): 861–79. doi:10.2174/138945006777709593. PMID 16842217.
Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, et al. (March 2002). "Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel". Clinical Cancer Research. 8 (3): 670–8. PMID 11895894.